Press releaseGlobe Newswire
Upstream Bio
UPB · NASDAQ
$2.82+$0.02 (+0.71%)TodayMarket closed ·
Prev close $2.80
Latest news
- Press releaseGlobe Newswire
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
- Press releaseGlobe Newswire
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress
- Press releaseGlobe Newswire
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
- Press releaseGlobe Newswire
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference
- Press releaseGlobe Newswire
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
- NewsVandana Singh
From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation Blocker
- NewsVandana Singh
Upstream Bio Lead Drug Pivotal Trial Plan Follows Strong Phase 2 Data
- Press releaseGlobe Newswire
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results
- Press releaseGlobe Newswire
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting
- Press releaseGlobe Newswire
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- NewsVandana Singh
Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns
- NewsAvi Kapoor
Crude Oil Gains Over 1%; US Economy Adds 130,000 Jobs In January
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsVandana Singh
Upstream Bio Shows Asthma Drug Cuts Attacks By 56%, Stock Reacts
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releaseGlobe Newswire
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
- Press releaseGlobe Newswire
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma
- NewsVandana Singh
Upstream's New Sinus Treatment Cuts Need For Surgery, Early Trial Finds
- NewsAvi Kapoor
Canopy Growth, Nvidia And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
- Press releaseGlobe Newswire
Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
- Press releaseGlobe Newswire
Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
- NewsAvi Kapoor
Alerus Financial Posts Better-Than-Expected Earnings, Joins Celcuity, SES AI, Abercrombie & Fitch And Other Big Stocks Moving Higher On Monday
- Press releaseBusiness Wire
Omega Funds Closes Oversubscribed $647 Million Fund VIII to Invest in Transformative Life Science Companies
- NewsAvi Kapoor
Amtech Systems, Tesla And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
- Press releasePRNewswire
Automotive Security Leaders Must Take Immediate Action to Mitigate the Surging Cyber Threats--Upstream Report Reveals Critical Gaps
- NewsVandana Singh
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.